|Principal Investigator: Brian Mickey|
|Keywords: Substance Use , TMS||Department: Psychiatry|
|IRB Number: 00130589|
|Sub Specialties: Addiction Psychiatry|
|Recruitment Status: Recruiting|
The purpose of this study is to evaluate the feasibility of a study protocol and provide pilot data to support a future sham-controlled clinical trial of transcranial magnetic stimulation (TMS) therapy for people with methamphetamine use disorder (MAUD).
Aim 1: Characterize changes in craving, depressive symptoms, anxiety symptoms, sleep quality, quality of life, and methamphetamine (MA) or other stimulant use over 4 weeks of dual-target TMS and 8 weeks of subsequent follow-up.
Aim 2: Estimate changes in functional connectivity and metabolite levels in the brain and response inhibition and selective attention as measured by a flanker task in people with MAUD after 4 weeks of dual-target TMS.
Aim 3: Evaluate retention in the study to establish feasibility and tolerability of the protocol.
- Age 18 to 60 years
- Diagnosed with an active methamphetamine use disorder, with use within the past month
- Planning to engage in psychosocial treatment for methamphetamine use disorder during the study period
- Capacity to consent for treatment and research participation
- History of seizure, active neurological disease, or use of medications that may increase seizure risk (e.g., clozapine, bupropion)
- Other contraindication to TMS or MRI (see attached screening forms)
- Clinically significant heart or kidney disease or hemodynamic instability
- Pregnancy or intent to become pregnant
- Active heavy alcohol use
- Bipolar disorder or schizophrenia-spectrum disorder
- Inability to complete the protocol due to travel, work, etc.